Showing 47 results
-
Media Release /Psoriatic arthritis is a chronic, autoimmune disease form of arthritis that causes joint inflammation (swelling, pain, stiffness) and occurs with skin condition psoriasis. It can also affect the…
-
Media Release /Approval is based on the two largest Phase III trials conducted in HS – SUNSHINE and SUNRISE – demonstrating the safety and efficacy of Cosentyx® in HS1HS is a chronic, immunological, inflammatory…
-
Media Release /More than 90,000 Canadians—or one in 400 people across Canada—live with multiple sclerosis (MS),1 a neurodegenerative, chronic condition that affects the central nervous system.2Despite decades…
-
Media Release /Montréal, QC, March 21, 2024 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by…
-
Media Release /Montreal, Quebec, December 5, 2023 — Novartis Canada announces that Mark Vineis has been appointed to the role of Country President, effective as of January 1, 2024. Mark brings a wealth of…
-
Media Release /Novartis has a long-standing history in Canada, and is committed to delivering improved outcomes for millions of patients. In 2022, Novartis invested a total of $450 million in Canada.The office has…
-
Media Release /Novartis has begun collaborating with seven clinics across the province to support the prevention, identification and management of atherosclerotic cardiovascular disease (ASCVD) In Ontario,…
-
Media Release /Luxturna® (voretigene neparvovec) is a one-time gene therapy that provides healthy copies of the RPE65 gene for retinal cells that are lacking the normally functioning gene1 Dorval, QC, September…
-
Media Release /Novel mechanism of action of PLUVICTO™ binds to target PSMA-positive cancer cells, delivering radiation treatment directly to those cells and nearby cells1 Prostate cancer is the most diagnosed…
-
Media Release /Scemblix provides a new option for chronic myeloid leukemia (CML) patients who have had two or more previous tyrosine kinase inhibitor (TKI) treatments1 New mechanism of action with Scemblix…
